Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000539 | 0.89 | HRH3 (0.53) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL16000538 | 0.89 | HRH3 (0.53) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL12122183 | 0.89 | HRH3 (0.53) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL25081503 | 0.84 | HRH3 (0.42) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL25081529 | 0.84 | HRH3 (0.42) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL26999673 | 0.84 | PDK1 (0.50) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL25081505 | 0.80 | HRH3 (0.40) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL25081526 | 0.80 | HRH3 (0.40) | HRH3PDK1ERBB2EPHA2KDR | |
| SCHEMBL16939080 | 0.75 | PDK1 (0.37) | HRH3PDK1EPHA2KCNH2 | |
| SCHEMBL13229791 | 0.75 | PDK1 (0.37) | HRH3PDK1EPHA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HRH3 994/4885PDK1 1969/4885ERBB2 2729/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | HRH3 994/4885PDK1 1969/4885ERBB2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.